在两项研究中，主要功效评估指标是无进展生存期。
In both studies, the primary efficacy endpoint was progression-free survival.
这两次研究基于不同国家：只有秘鲁，赞比亚和越南同时在两项研究中出现。
The two studies are based on different sets of countries: only Peru, Zambia and Vietnam appear in both.
在两项研究中，患者服用欣百达后，报告的常见副作用包括恶心、口干、疲劳、腹泻、过量出汗(多汗症)、头晕和便秘。
In both studies, side effects more commonly reported by patients taking Cymbalta included nausea, dry mouth, fatigue, diarrhea, excessive sweating (hyperhidrosis), dizziness, and constipation.
应用推荐